Promoter hypermethylation of Wnt inhibitory factor-1 in patients with lung cancer A systematic meta-analysis

Medicine (United States)

Volumn 95, Issue 49, 2016, Pages e5433-

  Zheng, Yu ^a   Li, Xia ^b   Jiang, Yiming ^b   Xu, Yufen ^b   Song, Binbin ^b   Zhou, Qiang ^b   Liang, Xiaodong ^c   Yang, Xinmei ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b JIAXING UNIVERSITY   (China)

^c ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Biomarker; Clinical significance; Hypermethylation; Lung cancer; WIF 1

Indexed keywords

TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WNT INHIBITORY FACTOR 1; REPRESSOR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; WIF1 PROTEIN, HUMAN; WNT1 PROTEIN; WNT1 PROTEIN, HUMAN;

ARTICLE; ASIAN; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; DNA METHYLATION; ETHNICITY; HUMAN; LUNG CANCER; META ANALYSIS; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROMOTER REGION; RECURRENCE FREE SURVIVAL; SYSTEMATIC REVIEW; EPIDEMIOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; MALE; NON SMALL CELL LUNG CANCER; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; SMALL CELL LUNG CANCER;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOMA, NON-SMALL-CELL LUNG; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; PROGNOSIS; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; SMALL CELL LUNG CARCINOMA; WNT1 PROTEIN;

EID: 85007421356     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000005433     Document Type: Article

References (37)

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2. Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008;13(suppl 1):5-13.
3. Niu PG, Zhang YX, Shi DH, et al. Cardamonin inhibits metastasis of Lewis lung carcinoma cells by decreasing mTOR activity. PLoS One 2015;10:e0127778.
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
5. Chakravarthi BV, Nepal S, Varambally S. Genomic and epigenomic alterations in cancer. Am J Pathol 2016;186:1724-35.
6. Quilichini E, Haumaitre C. Implication of epigenetics in pancreas development and disease. Best Pract Res Clin Endocrinol Metab 2015;29:883-98.
7. Khan SA, Reddy D, Gupta S. Global histone post-translational modifications and cancer: biomarkers for diagnosis, prognosis and treatment? World J Biol Chem 2015;6:333-45.
8. Ngollo M, Dagdemir A, Karsli-Ceppioglu S, et al. Epigenetic modifications in prostate cancer. Epigenomics 2014;6:415-26.
9. Rasmussen KD, Helin K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev 2016;30:733-50.
10. Kolla V, Zhuang T, Higashi M, et al. Role of CHD5 in human cancers: 10 years later. Cancer Res 2014;74:652-8.
11. Dudley JC, Lin MT, Le DT, et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 2016;22:813-20.
12. Ouadid-Ahidouch H, Rodat-Despoix L, Matifat F, et al. DNA methylation of channel-related genes in cancers. Biochim Biophys Acta 2015;1848(10 Pt B):2621-8.
13. Paul S, Dey A. Wnt signaling and cancer development: therapeutic implication. Neoplasma 2008;55:165-76.
14. Mazieres J, He B, You L, et al. Wnt signaling in lung cancer. Cancer Lett 2005;222:1-0.
15. Mazieres J, He B, You L, et al. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 2004;64:4717-20.
16. Hsieh JC, Kodjabachian L, Rebbert ML, et al. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 1999;398:431-6.
17. Tang Y, Simoneau AR, Liao WX, et al. WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Molec Cancer Therapeut 2009;8:458-68.
18. Kim J, You L, Xu Z, et al. Wnt inhibitory factor inhibits lung cancer cell growth. J Thorac Cardiovasc Surg 2007;133:733-7.
19. Paluszczak J, Sarbak J, Kostrzewska-Poczekaj M, et al. The negative regulators of Wnt pathway-DACH1, DKK1, and WIF1 are methylated in oral and oropharyngeal cancer and WIF1 methylation predicts shorter survival. Tumour Biol 2015;36:2855-61.
20. Zhang J, Zhou B, Liu Y, et al. Wnt inhibitory factor-1 functions as a tumor suppressor through modulating Wnt/beta-catenin signaling in neuroblastoma. Cancer Lett 2014;348:12-9.
21. Licchesi JD, Westra WH, Hooker CM, et al. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 2008;29:895-904.
22. Yoshino M, Suzuki M, Tian L, et al. Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers. Int J Oncol 2009;35:1201-9.
23. Tang M, Torres-Lanzas J, Lopez-Rios F, et al. Wnt signaling promoter hypermethylation distinguishes lung primary adenocarcinomas from colorectal metastasis to the lung. Int J Cancer 2006;119:2603-6.
24. Zintzaras E, Ioannidis JP. HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics 2005;21:3672-3.
25. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
26. DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Stat Med 1996;15:1237-48; [discussion 1249-52].
27. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
28. Lee SM, Park JY, Kim DS. Wif1 hypermethylation as unfavorable prognosis of non-small cell lung cancers with EGFR mutation. Mol Cells 2013;36:69-73.
29. Yang TM, Leu SW, Li JM, et al. WIF-1 promoter region hyper-methylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions. J Cancer Res Clin Oncol 2009;135:919-24.
30. Suzuki M, Shigematsu H, Nakajima T, et al. Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer. Clin Cancer Res 2007;13:6087-92.
31. Liu MD, Gong HY, Tan SP, et al. Detection of promoter hyper-methylation of WIF-1 gene by nested methylation specific polymerase chain reaction in lung cancer patients. Life Sci Res 2009;13:443-7.
32. Xu XJ, Ding WB, Han Y, et al. Study of abnormal methylation of the canonical Wnt signaling pathway-related genes in lung carcinoma carcinogenesis. Guangdong Med J 2008;29:899-901.
33. Maziveyi M, Alahari SK. Breast cancer tumor suppressors: a special emphasis on novel protein nischarin. Cancer Res 2015;75:4252-9.
34. Paluszczak J, Hemmerling D, Kostrzewska-Poczekaj M, et al. Frequent hypermethylation of WNT pathway genes in laryngeal squamous cell carcinomas. J Oral Pathol Med 2014;43:652-7.
35. Mitsui Y, Yasumoto H, Nagami T, et al. Extracellular activation of Wnt signaling through epigenetic dysregulation of Wnt inhibitory factor-1 (Wif-1) is associated with pathogenesis of adrenocortical tumor. Oncotarget 2014;5:2198-207.
36. Guo Y, Guo W, Chen Z, et al. Hypermethylation and aberrant expression of Wnt-antagonist family genes in gastric cardia adenocarci-noma. Neoplasma 2011;58:110-7.
37. Huang T, Chen X, Hong Q, et al. Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients. Sci Rep 2015;5:8897.